Core Viewpoint - Bath & Body Works, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between June 4, 2024, and November 9, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that the company's strategy of pursuing "adjacencies, collaborations and promotions" did not effectively grow the customer base or deliver the expected growth in net sales [1] - It is alleged that as the company's strategy faltered, it relied on brand collaborations to mask weak underlying financial results [1] - The complaint suggests that the company was unlikely to meet its previously issued financial guidance, and that positive statements made by the defendants about the company's business were materially misleading [1] Group 2: Investor Information - Investors who suffered losses during the relevant time frame have until March 13, 2026, to request to be appointed as lead plaintiff [1] - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [1] - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [1]

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 31, 2026 in Ramaco Lawsuit - METC [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ramaco Resources, Inc. ("Ramaco" or the "Company") (NASDAQ: METC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ramaco investors who were adversely affected by alleged securities fraud between July 31, 2025 and October ...

Shareholders of agilon health, inc. Should Contact Levi & Korsinsky Before March 2, 2026 to Discuss Your Rights - AGL [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in agilon health, inc. ("agilon health, inc." or the "Company") (NYSE: AGL) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of agilon health, inc. investors who were adversely affected by alleged securities fraud betwee ...

Core Viewpoint - The law firm Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against NuScale Power Corporation, alleging violations of the Securities Exchange Act of 1934 related to misleading statements about its commercialization partnership with ENTRA1 Energy LLC and the performance of its technology [1][3]. Company Overview - NuScale Power Corporation is involved in the development of small modular nuclear reactors, specifically the NuScale Power Module (NPM), aimed at generating energy within larger power plants [2]. - The company entered a global commercialization partnership with ENTRA1 Energy LLC, which was expected to advance its NPM technology from development to deployment [2]. Allegations of the Lawsuit - The lawsuit claims that NuScale and its executives made false statements regarding ENTRA1's capabilities, including that ENTRA1 had no significant experience in building or operating nuclear power projects [3]. - It is alleged that NuScale's reliance on ENTRA1 exposed the company to undisclosed risks, including potential failures and regulatory challenges [3]. Financial Impact - On November 6, 2025, NuScale reported a dramatic increase in general and administrative expenses, which rose over 3,000% to $519 million from $17 million in the previous year, primarily due to a $495 million payment to ENTRA1 [4]. - The company's quarterly net loss surged to $532 million, up from $46 million in the prior year, following the announcement of the TVA agreement [4]. - Following the financial disclosures, NuScale's Class A shares dropped more than 12% over two days [4]. Legal Process - Investors who purchased NuScale Class A common stock during the specified class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [6]. - The lead plaintiff can select a law firm to litigate the case, and participation as lead plaintiff is not required for investors to share in any potential recovery [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is recognized as a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering a total of $8.4 billion for investors over the past five years [7].

Core Points - The law firm Robbins Geller Rudman & Dowd LLP is announcing a class action lawsuit against CoreWeave, Inc. for alleged violations of the Securities Exchange Act of 1934 during the Class Period from March 28, 2025, to December 15, 2025 [1][3] Allegations - CoreWeave is accused of overstating its ability to meet customer demand and failing to disclose risks associated with reliance on a single third-party data center supplier, which could negatively impact revenue [3] - The lawsuit highlights a significant deal worth up to $11.9 billion with OpenAI announced shortly before CoreWeave's IPO and a subsequent all-stock acquisition agreement with Core Scientific, Inc. [2] Key Events - On October 30, 2025, Core Scientific announced it did not receive enough shareholder votes to approve its merger with CoreWeave, leading to a more than 6% drop in CoreWeave's share price [4] - On November 10, 2025, CoreWeave lowered its revenue guidance for 2025 due to delays from a third-party data center developer, resulting in a more than 16% decline in share price [5] - A December 15, 2025 article from The Wall Street Journal revealed greater-than-acknowledged delays in data center deliveries, causing an additional 3.4% drop in CoreWeave's share price [6] Legal Process - Investors who purchased CoreWeave securities during the Class Period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to act on behalf of other class members [7] - The lead plaintiff can select a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [8] About the Law Firm - Robbins Geller Rudman & Dowd LLP is a leading firm in complex class action litigation, having recovered over $916 million for investors in 2025 alone, and $8.4 billion over the past five years [9]

Core Viewpoint - Hub Group Inc. is under investigation for potential violations of federal securities laws, specifically regarding misrepresentation of transportation costs and accounts payable for the first nine months of 2025 [1][2]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into Hub Group for possible misrepresentation of its financial data [1][2]. - The investigation focuses on whether Hub Group inaccurately reported its purchased transportation costs and accounts payable [2]. Group 2: Stock Performance - Hub Group announced a delay in the release of its fourth quarter and full year 2025 financial results on February 5, 2026, due to an error that understated purchased transportation costs and accounts payable [3]. - Following this announcement, Hub Group's stock price dropped over 24% during trading on February 6, 2026 [4].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of New York, captioned Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. - Investors have until April 3, 2026, to request to be appointed to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Background - Plug Power specializes in hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets, and develops infrastructure such as hydrogen production plants [4]. - The company announced a $1.66 billion loan guarantee from the U.S. Department of Energy to finance the construction of hydrogen production projects [4]. Group 3: Stock Performance and Events - On October 7, 2025, Plug Power's stock dropped by $0.26 per share (6.3%) following the abrupt departure of its CEO and President [5]. - On November 10, 2025, the company suspended activities under the DOE loan program, leading to a stock drop of $0.09 per share (3.4%) [6]. - A report on November 13, 2025, confirmed the suspension of plans to construct hydrogen production facilities, resulting in a stock drop of $0.48 per share (17.6%) [7].

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit against Ardent Health, Inc. (NYSE:ARDT) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. If you invested in Ardent Health, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ardent-health-inc-class-act ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug setrusumab during the specified class period [2][4][7]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [2][7]. - The complaint alleges that Ultragenyx made false statements about the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients and downplayed risks associated with clinical trial results [4][7]. - Investors have until April 6, 2026, to file for lead plaintiff status in the lawsuit [2][9]. Group 2: Stock Performance - On December 29, 2025, Ultragenyx's stock price dropped over 42%, falling from $34.19 per share to $19.72 per share after the company announced that its Phase III studies did not achieve statistical significance [5][7]. Group 3: Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to discuss their legal rights [3][10]. - Options for investors include filing to be a lead plaintiff by the deadline or choosing to remain an absent class member [9].

Core Points - A securities fraud class action lawsuit has been filed against Kyndryl Holdings, Inc. for alleged material misstatements and omissions regarding cash management practices and internal controls over financial reporting [1] - The class period for the lawsuit is from August 7, 2024, to February 9, 2026, with a deadline of April 13, 2026, for investors to seek lead plaintiff status [1] - The lawsuit claims that Kyndryl's financial statements were materially misstated and that the company lacked adequate internal controls, leading to an inability to timely file its quarterly report with the SEC [1] Stock Performance - Kyndryl's stock price dropped over 54% following the announcement of the departure of the CFO and General Counsel on February 9, 2026, falling from $23.49 to $10.59 [1] - The company disclosed that it is reviewing its cash management practices and anticipates reporting material weaknesses in internal controls over financial reporting [1] Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to discuss legal rights [1] - Options for investors include retaining counsel, contacting KTMC, or filing to be a lead plaintiff by the specified deadline [1]